NASDAQ:ALEC Alector (ALEC) Stock Price, News & Analysis $2.16 +0.01 (+0.47%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$2.16 +0.00 (+0.23%) As of 05/29/2026 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Alector Stock (NASDAQ:ALEC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Alector alerts:Sign Up Key Stats Today's Range$2.05▼$2.2550-Day Range$2.00▼$2.7052-Week Range$1.09▼$3.40Volume993,189 shsAverage Volume593,756 shsMarket Capitalization$239.81 millionP/E RatioN/ADividend YieldN/APrice Target$3.63Consensus RatingHold Company Overview Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia. The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies. Alector designs its molecules to engage key immune receptors in the brain, seeking to slow or halt disease progression rather than simply address symptoms. Research and development activities are supported by state-of-the-art laboratories in North America and collaborations with academic and industry partners in Europe. Since completing its initial public offering in 2019, Alector has expanded its clinical footprint through strategic alliances and investigator-initiated trials. The company maintains global development programs aimed at bringing the first approved immuno-neurology therapies to patients worldwide. Alector is led by co-founder and Chief Executive Officer Dr. Arnon Rosenthal, a neuroscientist with over two decades of experience in immunology and drug discovery. The management team brings extensive backgrounds in clinical development, regulatory affairs, and commercialization, supporting Alector’s mission to transform the treatment landscape for neurodegenerative diseases.AI Generated. May Contain Errors. Read More Alector Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreALEC MarketRank™: Alector scored higher than 68% of companies evaluated by MarketBeat, and ranked 289th out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingHold Consensus RatingAlector has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and 2 sell ratings.Upside PotentialAlector has a consensus price target of $3.63, representing about 67.8% upside from its current price of $2.16.Amount of Analyst CoverageAlector has only been the subject of 4 research reports in the past 90 days.Read more about Alector's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Alector are expected to grow in the coming year, from ($0.86) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alector is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alector is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlector has a P/B Ratio of 24.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alector's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.77% of the float of Alector has been sold short.Short Interest Ratio / Days to CoverAlector has a short interest ratio ("days to cover") of 9.19.Change versus previous monthShort interest in Alector has recently decreased by 2.84%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlector does not currently pay a dividend.Dividend GrowthAlector does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment1.87 News SentimentAlector has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Alector this week, compared to 4 articles on an average week. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,473.00 in company stock.Percentage Held by Insiders8.30% of the stock of Alector is held by insiders.Percentage Held by Institutions85.83% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alector's insider trading history. Receive ALEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALEC Stock News HeadlinesAlector, Inc. (NASDAQ:ALEC) Given Consensus Recommendation of "Hold" by BrokeragesMay 30 at 2:43 AM | americanbankingnews.comAlector Establishes $125 Million At-the-Market OfferingMay 10, 2026 | theglobeandmail.comTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, changes behind the scenes may be opening the door to new cash-flow opportunities designed to generate regular monthly income — without requiring investors to pick individual stocks or predict market direction. In a new briefing, he explains how the structure works and what investors should understand before considering it.May 30 at 1:00 AM | Investors Alley (Ad)Alector Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 7, 2026 | globenewswire.comRetinal scan research offers hope for early Alzheimer’s detectionMay 2, 2026 | msn.comPeninsula biotech Alector loses another Alzheimer's battle, shifts to earlier-stage programsApril 30, 2026 | bizjournals.comHow The Alector (ALEC) Narrative Is Shifting Toward BBB Shuttle Programs And Execution RiskApril 30, 2026 | finance.yahoo.comAlector Stops Phase 2 Trial for Early Alzheimer's TreatmentApril 30, 2026 | marketwatch.comSee More Headlines ALEC Stock Analysis - Frequently Asked Questions How have ALEC shares performed this year? Alector's stock was trading at $1.56 at the beginning of the year. Since then, ALEC shares have increased by 38.5% and is now trading at $2.16. How were Alector's earnings last quarter? Alector, Inc. (NASDAQ:ALEC) announced its quarterly earnings data on Thursday, May, 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.08. The business had revenue of $1.05 million for the quarter, compared to analysts' expectations of $9.67 million. Alector had a negative trailing twelve-month return on equity of 295.17% and a negative net margin of 680.83%. Does Alector have any subsidiaries? Alector subsidiaries include Alector LLC. When did Alector IPO? Alector (ALEC) raised $176 million in an initial public offering (IPO) on Thursday, February 7th 2019. The company issued 9,250,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO. Who are Alector's major shareholders? Alector's top institutional shareholders include Spruce Street Capital LP (1.89%), Eversept Partners LP (1.22%), Renaissance Technologies LLC (1.16%) and ADAR1 Capital Management LLC (0.95%). Insiders that own company stock include Polaris Venture Management Co, Arnon Rosenthal, Sara Kenkare-Mitra, Neil Lindsay Berkley, Marc Grasso, Gary Romano, Grace Wong-Sarad, Kristine Yaffe and Paula Hammond. View institutional ownership trends. How do I buy shares of Alector? Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alector own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alector investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Enovix (ENVX), Meta Platforms (META), Rambus (RMBS), Saia (SAIA) and Tesla (TSLA). Company Calendar Last Earnings5/07/2026Today5/30/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ALEC's financial health is in the Green zone, according to TradeSmith. ALEC has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALEC CIK1653087 Webwww.alector.com Phone(415) 231-5660FaxN/AEmployees270Year Founded2013Price Target and Rating Average Price Target for Alector$3.63 High Price Target$6.00 Low Price Target$1.50 Potential Upside/Downside+67.8%Consensus RatingHold Rating Score (0-4)2.13 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$142.93 million Net Margins-680.83% Pretax Margin-679.91% Return on Equity-295.17% Return on Assets-40.95% Debt Debt-to-Equity Ratio0.80 Current Ratio5.25 Quick Ratio5.25 Sales & Book Value Annual Sales$18.42 million Price / Sales13.02 Cash FlowN/A Price / Cash FlowN/A Book Value$0.09 per share Price / Book24.00Miscellaneous Outstanding Shares111,025,000Free Float101,810,000Market Cap$239.81 million OptionableOptionable Beta0.64 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ALEC) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | SponsoredMusk takes on IranIranian drones have struck Amazon's data centers, with Microsoft, Google, Oracle, and Nvidia reportedly next o...Brownstone Research | SponsoredThe Great Repricing Has BegunThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredLegendary Stock Bull Says: “Brace for an Epic Price Crash”For 41 years, Alexander Green urged investors to buy stocks - calling Apple at $1, Netflix at $2, and NVIDIA a...The Oxford Club | SponsoredHer 0DTE system hits 87% of the timeA Wall Street insider's 0DTE options system claims an 87 percent hit rate by tracking where institutional mone...Trade To Close | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alector With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
